Press Release

Aspen Neuroscience Announces Expansion of Autologous Cell Therapy Manufacturing in San Diego

by
Aspen Neuro Manuf QC Team

Company Outlines Plans for Industrialization of Personalized Cell Therapy Manufacturing SAN DIEGO, Oct. 1, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing personalized (autologous) cell therapies, announced the expansion of its San Diego footprint near its headquarters in Torrey Pines, with a new 22,000 square foot facility for GMP manufacturing of induced pluripotent stem cell (iPSC)-derived cell … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at Upcoming Investor Conferences

by
Aspen Kameel Farag IMG 7524 Final e1727705111641

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ — Aspen Neuroscience Chief Financial Officer, Kameel Farag, will present this week at three biotechnology investor conferences, where he will provide company updates detailing Aspen’s latest developments and future strategic plans for treating neurodegenerative diseases, including Parkinson’s disease. About Aspen Neuroscience Aspen Neuroscience, Inc., headquartered in San Diego, is dedicated to autologous regenerative medicine. The company’s … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces Dosing Completion of First Cohort in ASPIRO Phase 1/2a Trial for Parkinson’s Disease

by
ClearPoint Filming Team

SAN DIEGO and PHILADELPHIA , Sept. 26, 2024 /PRNewswire/ — Aspen Neuroscience announced today that it has successfully completed dosing of the first cohort of patients in the ASPIRO study. Surgical safety data from this cohort has been accepted for late breaking presentations this week at the MDS International Congress of Parkinson’s Disease and Movement Disorders, taking place in Philadelphia September 27 … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Study of ANPD001 Autologous Neuronal Cell Replacement Treatment Approach Published in Journal of Neurosurgery

by
logo 23585

SAN DIEGO, July 29, 2024 /PRNewswire/ — The Journal of Neurosurgery has published online a study by the Wisconsin National Primate Research Center at the University of Wisconsin, Madison regarding a novel cell transplantation approach being used for delivery of ANPD001, an autologous, dopaminergic neuronal cell replacement under investigation by Aspen Neuroscience as a potential treatment for Parkinson’s Disease. The study by the Wisconsin … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at 2024 Raymond James Biotech Private Company Showcase July 18

by
Damien McDevitt

SAN DIEGO, July 17, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a clinical-stage private biotechnology company developing personalized regenerative therapies, announced today that president and CEO Damien McDevitt, PhD, will participate in a virtual fireside chat at the 2024 Raymond James Biotech Private Company Showcase on Thursday, July 18 at 11 a.m. PT / 2 p.m. ET. About Aspen NeuroscienceAspen Neuroscience, Inc., headquartered in San Diego, is … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at Stifel 2024 Cell Therapy Forum July 9

by
Untitled design 15

SAN DIEGO, July 8, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. a clinical-stage private biotechnology company developing personalized regenerative therapies, announced today that president and CEO Damien McDevitt, PhD, will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum this Tuesday, July 9 at 10:35am PT (1:35pm ET). A live webcast of the fireside chat will be broadcast … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Parkinson’s Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients’ Own Autologous Replacement Neurons

by
Untitled design 14

Aspen Neuroscience Announces MRI-Guided Transplantation Approach for ASPIRO Clinical Trial with the ClearPoint® Navigation System SAN DIEGO, June 20, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. announced today that it is utilizing the MRI-guided ClearPoint® Navigation System for all patients enrolled in the recently launched ASPIRO Phase 1/2a clinical trial for transplantation of dopaminergic neuron precursor cells (DANPCs) in patients … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at International Society for Cell & Gene Therapy (ISCT) Annual Meeting

by
Untitled design 13

Presentations Cover Aspen’s Autologous iPSC-derived Approach for Neuron Replacement Therapy in Trial for Parkinson’s Disease SAN DIEGO and VANCOUVER, BC, May 30, 2024 /PRNewswire/ — Aspen Neuroscience will present this week to a global audience of clinicians, regulators, researchers, technologists and industry partners at the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, May … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Receives CLIN2 Grant for ANPD001 from California Institute for Regenerative Medicine (CIRM)

by
Untitled design 11

Award Will Support the First U.S. Multi-center, Multi-patient Phase 1/2a Trial of an Autologous Neurological Therapy  SAN DIEGO, May 15, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a California-based private biotechnology company developing personalized regenerative therapies, has received a CLIN2 grant award of $8 million from the California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, to support … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease

by
cellimage001

First U.S. Multi-center, Multi-patient Phase 1/2a Trial of an Autologous Neurological Therapy SAN DIEGO, April 17, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo

Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2025 Aspen Neuroscience - All Rights Reserved